INOVIO Q3 net loss narrows to $0.15/sh; cash runway into Q1 2025

INOVIO PHARMACEUTICALS, INC.

2022-Q3 EPS reported -$0.96 revenue$10,137,602

Q3 2022 revenue of $9.2M vs $292K in Q3 2021, driven by DoD contract.
Net loss $37.8M ($0.15/sh) vs $60.2M ($0.29/sh) prior year; OpEx down to $44.9M.
Cash and investments $281.9M; guidance extended to early 2025 with ~$45M Q4 cash burn.
Discontinued internal INO-4800 heterologous COVID-19 booster; redeploying savings to other programs.
Positive interim INO-3107 data: median 3 fewer RRP surgeries; 29% needed no intervention in 52 weeks.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

INOVIO PHARMACEUTICALS, INC. reported third quarter and nine months ended September 30, 2022 results: revenue $9.2 million, net income $37.8 million, or $0.15 per basic and diluted share, EPS $0.15 per basic and diluted share.

Period: third quarter and nine months ended September 30, 2022
Revenue: $9.2 million
Net income: $37.8 million, or $0.15 per basic and diluted share
EPS: $0.15 per basic and diluted share
Result: reported results

Exact text from the filing

vesting, and conversion, as applicable, of its outstanding options, restricted stock units, convertible preferred stock, and convertible debt. INOVIO reported total revenue of $9.2 million for the three months ended, September 30, 2022, compared to $292,000 for the same period in 2021. The increase in revenue resulted from the fulfillment of obligations under its

View on SEC.gov

Browse all earnings releases →

INOVIO PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-22-280159

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.